Skip to main content
. 2023 Jan 3;15(1):169. doi: 10.3390/pharmaceutics15010169

Figure 3.

Figure 3

Preparation and characterization of P4 SLNs@DMNs. (A) Scheme of preparation process of P4 SLNs@DMNs. (B) The fluorescence images of P4 SLNs@DMNs (scale bar: 200 μm). (C) Optical microscopy images of P4 SLN@DMNs before and after insertion into gelatin (scale bar: 500 μm). (D) The fluorescence images of gelatin block after insertion of P4 SLNs@DMNs for 10 min (scale bar: 200 μm). (E) The histological section of back, abdomen, and ear skin of rats after P4 SLNs@DMNs application (scale bar: 100 μm) (F) Peak values of emission spectra of dissolved P4 SLNs@DMNs dispersions within ten days (n = 3). Data are expressed as mean ± SD.

HHS Vulnerability Disclosure